Non Hodgkin Lymphoma Clinical Trial
Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin’s Lymphoma
Summary
Conventional therapy is effective for diffuse aggressive lymphomas and low grade lymphomas, but is limited by relapse occurs in 40 to 50% of subjects.
This study assesses autologous stem cell transplant (ASCT) supplemented with high-dose therapy increases the event-free survival in diffuse aggressive lymphomas and low grade lymphomas, as an alternative to the limitations of conventional therapy.
Preliminary studies with rituximab in low grade lymphomas indicate a response rate of about 50% with very little toxicity. Rituximab is hypothesized to be a candidate for post-transplant therapy because the majority of malignant lymphomas express the CD20 antigen; rituximab has impressive independent anti-tumor activity; and the antibody has little toxicity outside of the acute administration.
Full Description
The first 4 subjects received rituximab weekly for 4 weeks at the standard dose of 375 mg/m2, starting 6 weeks after ASCT transplant.
After an observation period to assess acute and late toxicity for the first 4 subjects, subsequent subjects received induction as above followed by an additional 4 week course at 6-months post-ASCT.
Eligibility Criteria
Inclusion Criteria:
B-cell, CD20+ NHL
Evidence of engraftment post-autologous peripheral blood stem cell transplant (PBSC-T), aka autologous stem cell transplant (ASCT)
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
Creatinine < 2 mg/dL
Bilirubin < 2.0 mg/dL
Liver function tests (LFTs) < 5 x upper limit of normal (ULN)
Exclusion Criteria:
Graft source from bone marrow
Non-responders [progressive disease (PD) or stable disease (SD)] to prior anti-CD20 therapy
PD after ASCT
Post-ASCT radiotherapy
Concomitant treatment with radiotherapy, chemotherapy or immunotherapy including rituximab
Evidence of active pneumonitis
Evidence of active infection
Concurrent prednisone or other systemic steroid medication
Nitrosourea therapy within 6 weeks of the first treatment with rituximab
Presence of anti-murine antibody (HAMA) reactivity
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Stanford California, 94305, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.